Patents Represented by Attorney, Agent or Law Firm Charles M. Kinzig
  • 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
    Patent number: 6759410
    Abstract: The present invention relates to 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolines of formula (1), or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: July 6, 2004
    Assignee: SmithLine Beecham Corporation
    Inventors: Jerry L. Adams, Michael J. Bower, Ralph Hall, Don Edgar Griswold, David C. Underwood
  • Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminum phosphate
    Patent number: 6756040
    Abstract: The invention relates to a vaccine formulation for the prevention of Haemophilus Influenzae Type B (Hib) infections and where the antigen is adsorbed onto aluminum phosphate. The invention also relates to a multivalent vaccines, that is a vaccine for the amelioration or treatment of more than one disease states. The present invention also relates to the production and use of such vaccines in medicine.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: June 29, 2004
    Assignee: SmithKline Beecham Biologicals s.a.
    Inventors: Julien Peetermans, Pierre Hauser
  • 7-Alkoxycoumarins as CYP2C9 substrates and activity assay
    Patent number: 6756209
    Abstract: Coumarin derivatives as substrates for cytochrome P450 enzyme.
    Type: Grant
    Filed: June 11, 2001
    Date of Patent: June 29, 2004
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Ramesh B. Bambal, Richard Leonard Elliott
  • Amoxicillin and potassium clavulanate dosage form
    Patent number: 6756057
    Abstract: Bacterial infections may be treated using a high dosage regimen of amoxicillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: June 29, 2004
    Assignee: Beecham Pharmaceuticals (pte) Limited
    Inventors: Kevin H. Storm, Creighton P. Conley, John A. Roush
  • Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
    Patent number: 6750195
    Abstract: A compound which acts as an antagonist at 5-HT4 receptors is of potential use in the treatment of conditions associated with bladder hypersensitivity, such as urinary incontinence, which is often associated with irritable bowel syndrome (IBS) and a compound which acts as an agonist at 5-HT4 receptors is of potential use in the treatment of conditions associated with a poorly functioning bladder, such as urinary bladder hypoactivity following prostectomy.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: June 15, 2004
    Assignee: SmithKline Beecham Corporation p.l.c.
    Inventors: Gareth John Sanger, Kay Alison Wardle
  • Method of treatment of neuropsychiatric symptoms in patients with Alzheimer's Disease
    Patent number: 6750227
    Abstract: The use of [R-(Z)]-&agr;-(methoxyimino)-&agr;-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile or a pharmaceutically acceptable salt thereof for the treatment of neuropsychiatric symptoms in patients with Alzheimer's Disease is disclosed.
    Type: Grant
    Filed: February 21, 2003
    Date of Patent: June 15, 2004
    Assignees: SmithKline Beecham Corporation, SimthKline Beecham p.l.c.
    Inventors: Frank Brown, James P. Mc Cafferty, Eve Naomi Cedar
  • Screening methods using ligands of the neutropeptide receptor HFGAN72
    Patent number: 6750026
    Abstract: Polypeptides of HFGAN72 receptor ligands and polynucleotides encoding the polypeptides are provided. Methods of using these polypeptides to diagnose diseases relating to the under- or over-expression of HFGAN72 receptor ligands are also provided. In addition, methods of identifying agonists or antagonists of the interaction of HFGAN72 receptor ligands with the HFGAN72 receptor are provided. Methods of treatment by administering the identified agonists or antagonists to patients in need thereof are further disclosed.
    Type: Grant
    Filed: December 15, 2000
    Date of Patent: June 15, 2004
    Assignees: SmithKline Beecham Corporation, Board of Regents The University of Texas System
    Inventors: Derk J. Bergsma, David P. Brooks, Miklos Gellai, Shelagh Wilson, Masashi Yanagisawa
  • Piperazine derivatives as 5-HT1B antagonists
    Patent number: 6747030
    Abstract: Piperazine derivatives of formula(1), processes for their preparation, pharmaceutical compositions containing them in the treatment of CNS and other disorders and in their use in therapy as 5-HT1B antagonists are disclosed herein.
    Type: Grant
    Filed: March 25, 2002
    Date of Patent: June 8, 2004
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Howard Marshall, Mervyn Thompson, Paul Adrian Wyman
  • Modified release pharmaceutical formulation comprising amoxycillin
    Patent number: 6746692
    Abstract: Bacterial infections may be treated using a high dosage regimen of amoxycillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet.
    Type: Grant
    Filed: April 4, 2002
    Date of Patent: June 8, 2004
    Assignee: Beecham Pharmaceuticals (Pte) Limited
    Inventors: Creighton P. Conley, John A. Roush, Kevin H. Storm
  • Method for preparing cyclohexane carboxylic acids
    Patent number: 6740765
    Abstract: This invention relates to a method for preparing 4-substituted-4-cyanocyclohexane carboxylates by forming the cyclohexane ring by treating a &agr;,&agr;-bis(2-haloethyl)-4-benzeneacetonitrile with a dialkyl malonate and decarboxylating the resulting diester.
    Type: Grant
    Filed: April 2, 2002
    Date of Patent: May 25, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Ann M. Diederich, Ann Marie Eldridge, Robert J. Mills, Vance J. Novack
  • Fluorescent lanthanide chelates
    Patent number: 6740756
    Abstract: The present invention provides complexing agents of Formula I which contain novel photosensitizers and produce long-lived fluorescence for use in bioaffinity assays, especially HTRF (homogeneous time-resolved fluorescence) assays.
    Type: Grant
    Filed: June 20, 2001
    Date of Patent: May 25, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: George Wai-Kin Chan, Robert P. Hertzberg
  • Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
    Patent number: 6730683
    Abstract: Novel 1,4,5-substituted imidazole compounds and compositions for use in therapy as cytokine inhibitors.
    Type: Grant
    Filed: June 10, 2002
    Date of Patent: May 4, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Timothy Francis Gallagher, Jeffrey Charles Boehm, Jerry Leroy Adams
  • Pharmaceutical formulation
    Patent number: 6726908
    Abstract: This invention relates to pharmaceutical formulations comprising amoxycillin and a salt clavulanic acid in a ratio of 14:1.
    Type: Grant
    Filed: October 27, 1997
    Date of Patent: April 27, 2004
    Assignee: SmithKline Beecham p.l.c.
    Inventor: Daniel Joseph Burch
  • Fatty acid synthase inhibitors
    Patent number: 6723749
    Abstract: This invention relates to the use of compounds as inhibitors of the fatty acid synthase FabH.
    Type: Grant
    Filed: January 31, 2003
    Date of Patent: April 20, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Siegfried B. Christensen, Daniel J. Mercer, Jia-Ning Xiang
  • Liquid oral compositions comprising a calcium compound and an acidulant
    Patent number: 6719963
    Abstract: Acidic oral compositions having reduced tooth erosion characteristics, especially acid beverages such as fruit juice drink concentrates, or oral healthcare products such as mouthwashes, are prepared by adding a calcium compound to the acid composition so that the mol ratio of calcium to acid ranges from 0.3 to 0.8, and the pH of the composition, if necessary after adjustment with an alkali, is from 3.5 to 4.5.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: April 13, 2004
    Assignee: SmithKline Beecham p.l.c.
    Inventor: David Myatt Parker
  • Semicarbazone derivatives and their use as thrombopoietin mimetics
    Patent number: 6720345
    Abstract: Compounds of formula (I), particularly a compound of formula (Ia), are non-peptide TPO mimetics, useful in the treatment of thrombocytopenia.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: April 13, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Juan I. Luengo, Kevin J. Duffy, Antony N. Shaw
  • Controlled release formulation for treating COPD
    Patent number: 6713509
    Abstract: This invention relates to a controlled or sustained release formulation designed to deliver a PDE4 inhibitor for treating an inflammatory disease such as asthma or COPD and the like.
    Type: Grant
    Filed: August 22, 2001
    Date of Patent: March 30, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Patrick G. Faulkner, Jaime J. Lucca, Thomas J. Wrzosek
  • Anti-infectives
    Patent number: 6713502
    Abstract: Novel anti-infective and methods of using them are provided.
    Type: Grant
    Filed: November 5, 2002
    Date of Patent: March 30, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Dashyant Dhanak, Thomas Carr
  • Chromosomal DNA Fragments Encoding Enzymes for Encoding B-Lactam Biosynthesis Enzymes, and Vector and Transformants for Their Expression
    Patent number: 6709859
    Abstract: DNA sequences obtained from S. clavuligerus ATCC 27064, recombinant vectors incorporating such sequences and hosts transformed with such vectors are disclosed. The DNA comprises one or more genes coding for one or more enzymes involved in the biosynthesis of penicillin and cephalosporin &bgr;-lactams and such enzymes are expressed by hosts into which the recombinant vectors are transformed. The DNA and the enzymes encoded thereby have utility in the preparation of penicillins and cephalosporins, both known and novel, possessing pharmacological, especially antimicrobial, activity.
    Type: Grant
    Filed: January 10, 2000
    Date of Patent: March 23, 2004
    Assignee: Beecham Group p.l.c.
    Inventors: Martin Karl Rossel Burnham, Ian David Normansell, John Edward Hodgson
  • Bottle
    Patent number: D489626
    Type: Grant
    Filed: August 30, 2002
    Date of Patent: May 11, 2004
    Assignee: SmithKline Beecham Corporation
    Inventor: James L. Pitassi